Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials

European Journal of Cancer

Volumn 49, Issue 3, 2013, Pages 593-603

  Ciliberto, Domenico ^a   Botta, Cirino ^a   Correale, Pierpaolo ^b   Rossi, Marco ^a   Caraglia, Michele ^c   Tassone, Pierfrancesco ^a,d   Tagliaferri, Pierosandro ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Temple University   (United States)

Author keywords

Advanced pancreatic cancer; Combination therapy; Gemcitabine; Meta analysis

Indexed keywords

AXITINIB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIRUBICIN; ERLOTINIB; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PEMETREXED; TIPIFARNIB;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; META ANALYSIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HUMANS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872677684     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.08.019     Document Type: Article

References (75)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 1 2012 10 29
2. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 12 2010 2893 2917
3. M.H. Katz, C.Y. Hu, and J.B. Fleming Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer Arch Surg 2012
4. A. Vincent, J. Herman, R. Schulick, R.H. Hruban, and M. Goggins Pancreatic cancer Lancet 378 9791 2011 607 620
5. M. David, C. Lepage, and J.L. Jouve Management and prognosis of pancreatic cancer over a 30-year period Br J Cancer 101 2 2009 215 218
6. S. Nanda Cancer: pancreatic carcinomas metastasize at a late stage in their development Nat Rev Gastroenterol Hepatol 8 1 2011 4
7. H.A. Burris 3rd, M.J. Moore, and J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 1997 2403 2413
8. H. Burris, and A.M. Storniolo Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil Eur J Cancer 33 Suppl. 1 1997 S18 22
9. C.M. Rocha Lima, and A.M. Flores Gemcitabine doublets in advanced pancreatic cancer: should we move on? J Clin Oncol 24 3 2006 327 329
10. S.A. Welch, and M.J. Moore Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag? J Clin Oncol 25 16 2007 2159 2161
11. A. Sultana, C.T. Smith, D. Cunningham, N. Starling, J.P. Neoptolemos, and P. Ghaneh Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer J Clin Oncol 25 18 2007 2607 2615
12. V. Heinemann, S. Boeck, A. Hinke, R. Labianca, and C. Louvet Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 2008 82
13. M.J. Moore, D. Goldstein, and J. Hamm Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 15 2007 1960 1966
14. J.E. Ying, L.M. Zhu, and B.X. Liu Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol 18 8 2012 736 745
15. E. Bria, M. Milella, and A. Gelibter Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials Cancer 110 3 2007 525 533
16. L.A. Stewart, M.K. Parmar, and J.F. Tierney Meta-analyses and large randomized, controlled trials New Engl J Med 338 1 1998 61; author reply 2
17. M.K. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 24 1998 2815 2834
18. M.K. Parmar, L.A. Stewart, and D.G. Altman Meta-analyses of randomised trials: when the whole is more than just the sum of the parts Br J Cancer 74 4 1996 496 501
19. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
20. S. Armijo-Olivo, C.R. Stiles, N.A. Hagen, P.D. Biondo, and G.G. Cummings Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research J Eval Clin Pract 18 1 2012 12 18
21. A.S. Detsky, C.D. Naylor, K. O'Rourke, A.J. McGeer, and K.A. L'Abbe Incorporating variations in the quality of individual randomized trials into meta-analysis J Clin Epidemiol 45 3 1992 255 265
22. M. Crowther, W. Lim, and M.A. Crowther Systematic review and meta-analysis methodology Blood 116 17 2010 3140 3146
23. D. Wang, Z.Y. Mou, J.X. Zhai, H.X. Zong, and X.D. Zhao [Application of Stata software to test heterogeneity in meta-analysis method]. Zhonghua liu xing bing xue za zhi Zhonghua Liu Xing Bing Xue Za Zhi 29 7 2008 726 729
24. R. DerSimonian, and R.J. Levine Resolving discrepancies between a meta-analysis and a subsequent large controlled trial JAMA, J Am Med Assoc 282 7 1999 664 670
25. R. DerSimonian, and R. Kacker Random-effects model for meta-analysis of clinical trials: an update Contemp Clin Trials 28 2 2007 105 114
26. J.A. Sterne, A.J. Sutton, and J.P. Ioannidis Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials BMJ 343 2011 d4002
27. R.C. Boston, and A.E. Sumner STATA: a statistical analysis system for examining biomedical data Adv Exp Med Biol 537 2003 353 369
28. W. Scheithauer, B. Schull, and H. Ulrich-Pur Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial Ann Oncol 14 1 2003 97 104
29. J.D. Berlin, P. Catalano, J.P. Thomas, J.W. Kugler, D.G. Haller, and A.B. Benson 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 15 2002 3270 3275
30. Y. Nakai, H. Isayama, and T. Sasaki A multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study J Clin Oncol 28 Suppl. 15 2010 4037 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
31. H. Riess, A. Helm, and M. Niedergethmann A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer J Clin Oncol 23 Suppl. 16 2005 LBA4009 2005 ASCO Annual Meeting Proceedings
32. S. Ohkawa Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer J Clin Oncol 22 Suppl. 14 2004 4131 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
33. T. Ioka, M. Ikeda, and S. Ohkawa Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study J Clin Oncol 29 Suppl. 15 2011 4007 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
34. C.P. Li, and Y. Chao A prospective randomized trial of gemcitabine alone or gemcitabine + cisplatin in the treatment of metastatic pancreatic cancer J Clin Oncol 22 Suppl. 14 2004 4144 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
35. F. Viret, M. Ychou, and D. Lepille Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study J Clin Oncol 22 Suppl. 14 2004 4118 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
36. A. Goncalves, F. Viret, and E. François BAYPAN study: a double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer J Clin Oncol 29 Suppl. 15 2011 4028 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
37. H. Isayama, Y. Nakai, and T. Sasaki The final analysis of a multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study J Clin Oncol 29 Suppl. 15 2011 4040 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
38. J.A. Wright, J. Osterlee, S. Fekete, Y. Lee, and A.H. Young A phase III trial of virulizin plus gemcitabine vs. gemcitabine alone in advanced pancreatic cancer: results of subgroup analysis J Clin Oncol 24 Suppl. 18 2006 4116 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
39. S.J. Cohen, M.M. Zalupski, and P. Conkling A phase II randomized double blind multicenter trial of gemcitabine (Gem) plus imexon (IMX) versus Gem plus placebo (P) in patients with chemotherapy-naïve pancreatic adenocarcinoma (PC) J Clin Oncol 28 Suppl. 15 2010 4076 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
40. R. Herrmann, G. Bodoky, and T. Ruhstaller Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 16 2007 2212 2217
41. D. Cunningham, I. Chau, and D.D. Stocken Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 33 2009 5513 5518
42. F. Di Costanzo, P. Carlini, and L. Doni Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC) Br J Cancer 93 2 2005 185 189
43. H. Oettle, D. Richards, and R.K. Ramanathan A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer Ann Oncol 16 10 2005 1639 1645
44. G.K. Abou-Alfa, R. Letourneau, and G. Harker Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer J Clin Oncol 24 27 2006 4441 4447
45. M. Reni, S. Cordio, and C. Milandri Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial Lancet Oncol 6 6 2005 369 376
46. G. Colucci, F. Giuliani, and V. Gebbia Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 4 2002 902 910
47. G. Colucci, R. Labianca, and F. Di Costanzo Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study J Clin Oncol 28 10 2010 1645 1651
48. C. Louvet, R. Labianca, and P. Hammel Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 15 2005 3509 3516
49. V. Heinemann, D. Quietzsch, and F. Gieseler Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 24 2006 3946 3952
50. E. Poplin, Y. Feng, and J. Berlin Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group J Clin Oncol 27 23 2009 3778 3785
51. X. Wang, Q. Ni, and M. Jin Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer Zhonghua Zhong Liu Za Zhi [Chin J Oncol] 24 4 2002 404 407
52. E. Van Cutsem, H. van de Velde, and P. Karasek Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 8 2004 1430 1438
53. H.L. Kindler, D. Niedzwiecki, and D. Hollis Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303) J Clin Oncol 28 22 2010 3617 3622
54. H.L. Kindler, T. Ioka, and D.J. Richel Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study Lancet Oncol 12 3 2011 256 262
55. P.A. Philip, J. Benedetti, and C.L. Corless Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 J Clin Oncol 28 22 2010 3605 3610
56. J.P. Spano, C. Chodkiewicz, and J. Maurel Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study Lancet 371 9630 2008 2101 2108
57. S.R. Bramhall, J. Schulz, J. Nemunaitis, P.D. Brown, M. Baillet, and J.A. Buckels A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2 2002 161 167
58. D.A. Richards, P.R. Kuefler, and C. Becerra Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study Invest New Drugs 29 1 2011 144 153
59. H. Friess, J.M. Langrehr, and H. Oettle A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer BMC Cancer 6 2006 285
60. Y. Omuro, T. Ikari, and H. Ishii A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer J Clin Oncol 29 Suppl. 15 2011 4029 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
61. B.M. Wolpin, E.M. O'Reilly, Y. Ko, L.S. Blaszkowsky, and M.U. Rarick Rocha Lima CM, et al. Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC) J Clin Oncol 29 Suppl. 15 2011 4031 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
62. Z. Meng, L. Liu, and Y. Shen A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC) J Clin Oncol 29 Suppl. 15 2011 4127 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
63. C.M. Rocha Lima, M.R. Green, and R. Rotche Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 18 2004 3776 3783
64. G.P. Stathopoulos, K. Syrigos, and G. Aravantinos A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer Br J Cancer 95 5 2006 587 592
65. M.H. Kulke, M.A. Tempero, and D. Niedzwiecki Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904 J Clin Oncol 27 33 2009 5506 5512
66. B. Chuah, B.C. Goh, and S.C. Lee Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients Cancer Sci 102 2 2011 Feb 478 483
67. T. Conroy, F. Desseigne, and M. Ychou FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer New Engl J Med 364 19 2011 1817 1825
68. P. Correale, F. Montagnani, and S. Miano Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer J Chemother 20 1 2008 119 125
69. P. Correale, S. Messinese, and S. Marsili A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid Br J Cancer 89 2 2003 239 242
70. D.D. Von Hoff, R.K. Ramanathan, and M.J. Borad Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial J Clin Oncol 29 34 2011 4548 4554
71. G. Bodoky, C. Timcheva, and D.R. Spigel A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy Invest New Drugs 30 3 2012 1216 1223
72. N. Xenidis, L. Chelis, and K. Amarantidis Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study Cancer Chemother Pharmacol 69 2 2012 477 484
73. M. Hidalgo, and A. Maitra The hedgehog pathway and pancreatic cancer New Engl J Med 361 21 2009 2094 2096
74. K.P. Olive, M.A. Jacobetz, and C.J. Davidson Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 5933 2009 1457 1461
75. D.A. Richards, J. Stephenson, and B.M. Wolpin A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer J Clin Oncol 30 Suppl. 4 2012 213 2012 Gastrointestinal Cancers Symposium